# NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial

Study · id `cardio:ct-nct06141200` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06141200](<https://clinicaltrials.gov/study/NCT06141200>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06141200

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 286 participants.

## Technical summary

Registry record NCT06141200. Randomized; quadruple masking; primary purpose treatment. Start 2024-03 (anticipated); primary completion 2025-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 286 participants (planned count; ClinicalTrials.gov record NCT06141200, source copy `cardio:ctgov-nct06141200-2023-11-21`, retrieved 2026-10-26)
- Planned start: 2024-03 (anticipated) (ClinicalTrials.gov record NCT06141200, source copy `cardio:ctgov-nct06141200-2023-11-21`, retrieved 2026-10-26)
- Primary completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT06141200, source copy `cardio:ctgov-nct06141200-2023-11-21`, retrieved 2026-10-26)
- Completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT06141200, source copy `cardio:ctgov-nct06141200-2023-11-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06141200-2023-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial
- Condition: Essential Hypertension
- Intervention (Drug): NW Roselle
- Intervention (Drug): Captopril 25Mg Tab
- Lead sponsor: Natural Wellness Egypt
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: b18c7e15fb7ca14db85e29faeced80f0d820689583af87f8d831d9f8a4711c0b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
